专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明专利

SG10201913767VA ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF 未知
公开(公告)号：SG10201913767VA
公开(公告)日：2020-03-30
申请号：SG10201913767V
申请日：2016-05-04
申请人： CYTOMX THERAPEUTICS INC
发明人： WEST JAMES WILLIAM , SAGERT JASON GARY , TERRETT JONATHAN ALEXANDER , WEAVER ANNIE YANG , DESNOYERS LUC ROLAND , SINGH SHWETA
摘要： The invention relates generally to an-tibodies that bind CD166, activatable antibodies that specifically bind to CD 166 and methods of making and using these anti-CD166 antibodies and an-ti-CD166 activatable antibodies in a variety of thera-peutic, diagnostic and prophylactic indications.

82. 发明专利

SG10201913303XA ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF 未知
公开(公告)号：SG10201913303XA
公开(公告)日：2020-03-30
申请号：SG10201913303X
申请日：2016-07-13
申请人： CYTOMX THERAPEUTICS INC
发明人： TIPTON KIMBERLY ANN , WEST JAMES WILLIAM , CHAN CHANTY MARIATEGUE
摘要： The invention relates generally to antibodies that specifically bind programmed cell death protein 1 (PD-1), activatable antibodies that specifically bind to PD-1 and methods of making and using these anti-PD-1 antibodies and anti-PD-1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

83. 发明专利

AU2018347607A1 Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof 未知
公开(公告)号：AU2018347607A1
公开(公告)日：2020-03-26
申请号：AU2018347607
申请日：2018-10-12
申请人： CYTOMX THERAPEUTICS INC
发明人： BOUSTANY LEILA MARIE , LA PORTE SHERRY L , IRVING BRYAN A , FLANDEZ JEANNE GRACE
IPC分类号： C07K16/28
摘要： Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.

84. 发明专利

AU2014324884B2 Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof 未知
公开(公告)号：AU2014324884B2
公开(公告)日：2020-03-26
申请号：AU2014324884
申请日：2014-09-25
申请人： CYTOMX THERAPEUTICS INC
发明人： MOORE STEPHEN JAMES , NGUYEN MARGARET THY LUU , HOSTETTER DANIEL R , VASILJEVA OLGA , FLANDEZ JEANNE GRACE
IPC分类号： C07K16/18 , A61K39/395 , C07K16/46
摘要： The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.

85. 发明专利

AU2018300237A1 Anti-CD166 antibodies and uses thereof 未知
公开(公告)号：AU2018300237A1
公开(公告)日：2020-01-16
申请号：AU2018300237
申请日：2018-07-13
申请人： CYTOMX THERAPEUTICS INC
发明人： DESNOYERS LUC ROLAND , DUPAGE AMY GRACE
IPC分类号： C07K16/28
摘要： The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD 166 antibody or antigen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain ("ICD") of CD 166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166. In various embodiments, an anti-CD 166 antibody or antigen-binding polypeptide is useful in a method of detecting or treating a condition or disease.

86. 发明专利

PE20191131A1 ANTICUERPOS ANTI ANTIGENO 4 DEL LINFOCITO T CITOTOXICO (CTLA-4) ACTIVABLES Y SUS USOS 未知
公开(公告)号：PE20191131A1
公开(公告)日：2019-09-02
申请号：PE2019000902
申请日：2017-11-02
申请人： SQUIBB BRISTOL MYERS CO , CYTOMX THERAPEUTICS INC
发明人： TIPTON KIMBERLY ANN , WEST JAMES WILLIAM , DESHPANDE SHRIKANT , ENGELHARDT JOHN J
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , C07K19/00
摘要： SE REFIERE A UN ANTICUERPO ANTI-CTLA-4 HUMANO ACTIVABLE QUE COMPRENDE: I) UNA CADENA PESADA QUE COMPRENDE UN DOMINIO VARIABLE DE LA CADENA PESADA (VH) QUE COMPRENDE CDRH1 DE SEC ID NO: 557; CDRH2 DE SEC ID NO: 558; Y CDRH3 DE SEC ID NO: 559; Y II) UNA CADENA LIVIANA QUE COMPRENDE a) UN DOMINIO VARIABLE DE CADENA LIVIANA (VL) QUE COMPRENDE CDRL1 DE SEC ID NO: 560; CDRL2 DE SEC ID NO: 561; Y CDRL3 DE SEC ID NO: 562; b) UN RESTO ESCINDIBLE (CM); Y c) UN RESTO ENMASCARADOR (MM); DONDE DICHO ANTICUERPO ADEMAS COMPRENDE UN SEGUNDO PEPTIDO LIGADOR (LP2); UN AGENTE TOXICO Y UN RESTO DETECTABLE QUE ES UN AGENTE DE DIAGNOSTICO. TAMBIEN SE REFIERE A UN METODO PARA PRODUCIR UN ANTICUERPO ANTI-CTLA-4 HUMANO ACTIVABLE Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO, SIENDO UTIL EN EL TRATAMIENTO DEL CANCER DE VEJIGA, CANCER DE HUESO, MAMA, CUELLO UTERINO

87. 发明专利

BR112019008223A2 anticorpos anti-ctla-4 ativáveis e usos dos mesmos 未知
公开(公告)号：BR112019008223A2
公开(公告)日：2019-07-16
申请号：BR112019008223
申请日：2017-11-02
申请人： SQUIBB BRISTOL MYERS CO , CYTOMX THERAPEUTICS INC
发明人： JAMES WILLIAM WEST , JOHN J ENGELHARDT , KIMBERLY ANN TIPTON , SHRIKANT DESHPANDE
IPC分类号： A61K39/395 , A61P35/00 , C07K16/28 , C07K19/00
摘要： são fornecidos nesta invenção anticorpos anti-ctla-4 humanos ativáveis compreendendo uma cadeia pesada que compreende um domínio vh e uma cadeia leve que compreende uma porção de mascaramento (mm), uma porção clivável (cm) e um domínio vl. tais anticorpos anti-ctla-4 humanos ativáveis possuem atividade de ligação ao ctla-4 no microambiente tumoral, em que a porção de mascaramento é removido através da clivagem proteolítica da porção clivável por proteases específicas do tumor, mas apresentam ligação grandemente reduzida ao ctla-4 fora do tumor. deste modo, os anticorpos anti-ctla-4 humanos ativáveis da presente invenção retêm a atividade antitumoral enquanto reduz os efeitos colaterais associados com a atividade anti-ctla-4 fora do tumor.

88. 发明专利

SG11201902857SA ACTIVATABLE ANTI-CTLA-4 ANTIBODIES AND USES THEREOF 未知
公开(公告)号：SG11201902857SA
公开(公告)日：2019-05-30
申请号：SG11201902857S
申请日：2017-11-02
申请人： SQUIBB BRISTOL MYERS CO , CYTOMX THERAPEUTICS INC
发明人： TIPTON KIMBERLY ANN , WEST JAMES WILLIAM , DESHPANDE SHRIKANT , ENGELHARDT JOHN J
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , C07K19/00
摘要： 40 60 Days Post Implantation 'gr ' E 2500- 10/10 TF nE 2500 E 2000- E 2000 E 1500- E 1500 7 , 1000- 0 1000 500- 0 E 500 0 0 20 40 60 Days Post Implantation 8/10 TF 20 40 60 Days Post Implantation rTe E E 0 0 2500 2000 1500 1000 500 0 FIG. 9D YV23 2001 9/10 TF 20 40 60 Days Post Implantation FIG. 9E YV24 2001 2500 2000 1500 1000 500 0 FIG. 9F YV39 2001 2500 2000 1500 1000 500 0 Fsi E E E E C . 7 2500 E 2000 E 1500 0 1000 8 500 E 0 7/10 TF 20 40 60 Days Post Implantation E ‘ E ) o 0 E I- 10/101T 20 40 60 Days Post Implantation (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 1111111111110110101011111011110 100111MIONOITEREMOVIO# (10) International Publication Number WO 2018/085555 A8 11 May 2018 (11.05.2018) WIPO I PCT (51) International Patent Classification: CO7K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 19/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/059740 (22) International Filing Date: 02 November 2017 (02.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/417,212 03 November 2016 (03.11.2016) US (71) Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Rt. 206 & Province Line Road, Princeton, New Jersey 08543 (US). CYTOMX THERAPEUTICS, INC. [US/US]; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (72) Inventors: TIPTON, Kimberly Ann; c/o CytomX Thera- peutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). WEST, James William; c/o CytomX Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). DESHPANDE, Shrikant; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). ENGELHARDT, John J.; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). (74) Agent: CALVO, Paul A. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washing- ton, District of Columbia 20005 (US). (54) Title: ACTIVATABLE ANTI-CTLA-4 ANTIBODIES AND USES THEREOF FIG. 9A Control mg2a FIG. 9B !pi mg2a (YV1) FIG. 9C YV04 2001 (57) : Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 00 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage O of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the 00 activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated O with anti-CTLA-4 activity outside the tumor. O [Continued on next page] WO 2018/085555 A8 MIDEDIM01101 DIDIRE10111011111111111HHH11111111101111111111 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (48) Date of publication of this corrected version: 31 May 2018 (31.05.2018) (15) Information about Correction: see Notice of 31 May 2018 (31.05.2018)

89. 发明专利

CA3078911A1 ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF 未知
公开(公告)号：CA3078911A1
公开(公告)日：2019-04-18
申请号：CA3078911
申请日：2018-10-12
申请人： CYTOMX THERAPEUTICS INC
发明人： BOUSTANY LEILA MARIE , LA PORTE SHERRY L , IRVING BRYAN A , FLANDEZ JEANNE GRACE
IPC分类号： C07K16/28
摘要： Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.

90. 发明专利

ES2368387T5 Anticuerpos terapéuticos y que inducen tolerancia 未知
公开(公告)号：ES2368387T5
公开(公告)日：2019-03-07
申请号：ES01974480
申请日：2001-10-09
申请人： CYTOMX THERAPEUTICS INC
发明人： WALDMANN HERMAN , FREWIN MARK RAYMOND , GILLILAND LISA KIM , DA SILVA GRACA LUIS RICHARDO SIMOES
IPC分类号： A61K38/00 , A61K39/395 , A61K47/48 , A61P3/10 , A61P9/10 , A61P17/06 , A61P25/00 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/06 , A61P37/08 , C07K16/00 , C07K16/28 , C07K19/00

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式